Oruka Therapeutics (NASDAQ:ORKA) Trading Down 5.9% – Here’s Why

Oruka Therapeutics, Inc. (NASDAQ:ORKA) was down 5.9% during trading on Friday . The stock traded as low as $64.08 and last traded at $64.3510. Approximately 835,942 shares were traded during trading, a decline of 11% from the average daily volume of 939,022 shares. The stock had previously closed at $68.41.

Trending Headlines about Oruka Therapeutics

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: HC Wainwright raised multiple quarterly and full‑year EPS forecasts for ORKA and maintained a Buy rating with a $120 target, signaling stronger expected financial trajectory and continued analyst confidence.
• Positive Sentiment: Company reported positive Phase 2a results for ORKA‑001 in moderate‑to‑severe plaque psoriasis — clinical progress that materially de‑risks the program if durability and safety are confirmed. Oruka Therapeutics (ORKA) Reports Positive Phase 2a Results for Psoriasis Treatment ORKA-001
• Positive Sentiment: Detailed interim results and slides from the EVERLAST‑A study (ORKA‑001) were posted and discussed in investor commentary, providing more data for analysts and institutions to model the program’s potential. ORKA Discusses Interim Results From EVERLAST‑A Study
• Positive Sentiment: Stifel Nicolaus reaffirmed its Buy view on ORKA, adding another institutional vote of confidence in the stock’s outlook. Stifel Keeps Buy Rating on Oruka Therapeutics
• Neutral Sentiment: Oruka was highlighted in a list of “small‑cap stocks that are on fire,” which can boost retail attention but is not a substantive catalyst by itself. 5 Small‑Cap Stocks That Are On Fire Right Now
• Negative Sentiment: Oruka priced an upsized $700M public offering at $72.50 per share — a large secondary that creates near‑term dilution and typically pressures the stock; this is the most likely proximate cause of today’s sell‑off and elevated volume. Oruka Therapeutics Prices Upsized $700M Public Offering at $72.50

Wall Street Analyst Weigh In

Several research analysts have commented on ORKA shares. Barclays boosted their price target on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the stock an “overweight” rating in a report on Monday. Stifel Nicolaus boosted their price target on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the stock a “buy” rating in a report on Friday, March 13th. Leerink Partners set a $120.00 price target on shares of Oruka Therapeutics in a report on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Tuesday, April 21st. Finally, UBS Group boosted their price target on shares of Oruka Therapeutics from $75.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $120.80.

Oruka Therapeutics Trading Down 8.8%

The firm’s fifty day moving average price is $49.57 and its 200-day moving average price is $36.87. The firm has a market cap of $3.13 billion, a price-to-earnings ratio of -33.51 and a beta of -0.54.

Oruka Therapeutics (NASDAQ:ORKA) last issued its earnings results on Thursday, March 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.16. On average, sell-side analysts expect that Oruka Therapeutics, Inc. will post -2.25 earnings per share for the current year.

Insider Buying and Selling at Oruka Therapeutics

In other news, CEO Lawrence Otto Klein sold 1,729 shares of the company’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $41.30, for a total value of $71,407.70. Following the completion of the transaction, the chief executive officer owned 927,309 shares in the company, valued at approximately $38,297,861.70. This represents a 0.19% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Joana Goncalves sold 7,641 shares of the company’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $40.91, for a total transaction of $312,593.31. Following the completion of the sale, the insider owned 33,377 shares of the company’s stock, valued at approximately $1,365,453.07. This trade represents a 18.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 23,765 shares of company stock valued at $1,089,745. Company insiders own 24.69% of the company’s stock.

Institutional Trading of Oruka Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Fairmount Funds Management LLC raised its position in Oruka Therapeutics by 9.9% in the 3rd quarter. Fairmount Funds Management LLC now owns 3,705,262 shares of the company’s stock valued at $71,252,000 after purchasing an additional 333,340 shares during the last quarter. Secure Asset Management LLC purchased a new stake in Oruka Therapeutics in the 4th quarter valued at $2,475,000. Avoro Capital Advisors LLC purchased a new stake in Oruka Therapeutics in the 3rd quarter valued at $25,640,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management purchased a new stake in Oruka Therapeutics in the 3rd quarter valued at $296,000. Finally, Commodore Capital LP raised its position in Oruka Therapeutics by 23.5% in the 3rd quarter. Commodore Capital LP now owns 1,753,054 shares of the company’s stock valued at $33,711,000 after purchasing an additional 333,340 shares during the last quarter. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.